STA-5326 ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	1
96	Crohn disease	5

65. Primary immunodeficiency

Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00263237 (ClinicalTrials.gov)	December 2, 2005	7/12/2005	STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency	A Pilot Study of Safety and Efficacy of the Oral IL-12/23 Inhibitor, STA-5326Mesylate, for Symptomat ...	Common Variable Immunodeficiency	Drug: STA-5326	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	75 Years	All	10	Phase 1	United States

First Previous1Next Last

96. Crohn disease

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-002857-29-HU (EUCTR)	04/01/2006	18/08/2005	A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-53 ...	A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-53 ...	Moderate to severe, active Crohn’s disease MedDRA version: 3.2;Level: LLT;Classification code 100114 ...	Product Name: STA-5326 mesylate Product Code: S38 Other descriptive name: STA-6838, STA-5326 m, S38	Synta Pharmaceutical Corporation	NULL	Not Recruiting			Female: yes Male: yes	282		Hungary
2	NCT00250198 (ClinicalTrials.gov)	November 3, 2005	5/11/2005	The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease	A Randomized, Double-blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326Mesylate, to Investi ...	Crohn's Disease	Drug: STA-5326	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	75 Years	All	12	Phase 2	United States
3	NCT00234741 (ClinicalTrials.gov)	November 2005	5/10/2005	Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease	A Randomized, Double-Blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326Mesylate, to Investi ...	Crohn's Disease	Drug: STA-5326 mesylate	Synta Pharmaceuticals Corp.	National Institute of Allergy and Infectious Diseases (NIAID);National Institutes of Health (NIH)	Completed	18 Years	75 Years	Both	12	Phase 2	United States
4	NCT00138840 (ClinicalTrials.gov)	August 2005	26/8/2005	Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease	A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-53 ...	Crohn's Disease	Drug: STA-5326 mesylate	Synta Pharmaceuticals Corp.	NULL	Completed	18 Years	75 Years	Both	282	Phase 2	United States;Canada
5	NCT00088062 (ClinicalTrials.gov)	February 2004	19/7/2004	STA-5326 in Crohn's Disease Patients	A Phase I/IIa Trial of STA-5326 in Crohn's Disease Patients With CDAI Scores of 220-450	Crohn's Disease	Drug: STA-5326	Synta Pharmaceuticals Corp.	NULL	Completed	18 Years	65 Years	Both	48	Phase 1/Phase 2	United States

First Previous1Next Last